Business Description
Iovance Biotherapeutics Inc
NAICS : 325411
SIC : 2834
ISIN : US4622601007
Description
Iovance Biotherapeutics Inc is a clinical-stage biopharmaceutical company, pioneering a transformational approach to treating cancer by harnessing the human immune system's ability to recognize and destroy diverse cancer cells using therapies personalized for each patient. The company is preparing for potential U.S. regulatory approvals and commercialization of the first autologous T-cell therapy to address a solid tumor cancer. its objective is to be the leader in innovating, developing, and delivering tumor-infiltrating lymphocyte, or TIL, therapies for patients with solid tumor cancers.
Financial Strength
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 5.04 | |||||
| Equity-to-Asset | 0.78 | |||||
| Debt-to-Equity | 0.1 | |||||
| Debt-to-EBITDA | -0.2 | |||||
| Interest Coverage | N/A |
N/A
|
N/A
| |||
| Piotroski F-Score | 6/9 | |||||
| Altman Z-Score | 2.18 | |||||
| Beneish M-Score | 62.66 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year EBITDA Growth Rate | 0.2 | |||||
| 3-Year EPS without NRI Growth Rate | -0.2 | |||||
| 3-Year FCF Growth Rate | 3.6 | |||||
| 3-Year Book Growth Rate | -20.1 | |||||
| Future 3-5Y EPS without NRI Growth Rate | 48.58 | |||||
| Future 3-5Y Total Revenue Growth Rate | 647.64 |
Momentum Rank
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 12.12 | |||||
| 9-Day RSI | 23.99 | |||||
| 14-Day RSI | 31.8 | |||||
| 6-1 Month Momentum % | 3.89 | |||||
| 12-1 Month Momentum % | 18.81 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 4.22 | |||||
| Quick Ratio | 3.9 | |||||
| Cash Ratio | 3.37 | |||||
| Days Inventory | 91.33 | |||||
| Days Sales Outstanding | 88.14 | |||||
| Days Payable | 114.77 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -20.4 | |||||
| Shareholder Yield % | -17.38 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 8.85 | |||||
| Operating Margin % | -473.23 | |||||
| Net Margin % | -451.26 | |||||
| FCF Margin % | -415.23 | |||||
| ROE % | -58.9 | |||||
| ROA % | -45.99 | |||||
| ROIC % | -86.33 | |||||
| ROC (Joel Greenblatt) % | -239.24 | |||||
| ROCE % | -54.26 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PS Ratio | 24.3 | |||||
| PB Ratio | 2.94 | |||||
| Price-to-Tangible-Book | 4.89 | |||||
| EV-to-EBIT | -4.55 | |||||
| EV-to-Forward-EBIT | -5.78 | |||||
| EV-to-EBITDA | -5.03 | |||||
| EV-to-Forward-EBITDA | -6.35 | |||||
| EV-to-Revenue | 21.52 | |||||
| EV-to-Forward-Revenue | 4.23 | |||||
| EV-to-FCF | -5.23 | |||||
| Price-to-Net-Current-Asset-Value | 8.11 | |||||
| Price-to-Net-Cash | 12.53 | |||||
| Earnings Yield (Greenblatt) % | -21.98 | |||||
| FCF Yield % | -16.45 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Iovance Biotherapeutics Inc Executives
DetailsGF Value
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil €) | 82.754 | ||
| EPS (TTM) (€) | -1.367 | ||
| Beta | 0.82 | ||
| Volatility % | 130.73 | ||
| 14-Day RSI | 31.8 | ||
| 14-Day ATR (€) | 0.277742 | ||
| 20-Day SMA (€) | 8.1851 | ||
| 12-1 Month Momentum % | 18.81 | ||
| 52-Week Range (€) | 5.834 - 16.85 | ||
| Shares Outstanding (Mil) | 304.78 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 6 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Iovance Biotherapeutics Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Iovance Biotherapeutics Inc Stock Events
| Event | Date | Price(€) | ||
|---|---|---|---|---|
| No Event Data | ||||
Iovance Biotherapeutics Inc Frequently Asked Questions
What is Iovance Biotherapeutics Inc(FRA:2LB)'s stock price today?
The current price of FRA:2LB is €6.89. The 52 week high of FRA:2LB is €16.85 and 52 week low is €5.83.
When is next earnings date of Iovance Biotherapeutics Inc(FRA:2LB)?
The next earnings date of Iovance Biotherapeutics Inc(FRA:2LB) is 2025-02-28 Est..
Does Iovance Biotherapeutics Inc(FRA:2LB) pay dividends? If so, how much?
Iovance Biotherapeutics Inc(FRA:2LB) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers